<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Small molecule</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Fulcrum drops work on SCD drug pociredir; stock plummets</title>
      <description>
        <![CDATA[Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) fell 54% after the company said it is discontinuing work on sickle cell disease (SCD) candidate pociredir, its only clinical-stage candidate, and reviewing strategic alternatives in the wake of the U.S. FDA’s safety concerns regarding the drug target.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731532</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731532-fulcrum-drops-work-on-scd-drug-pociredir-stock-plummets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Sickle-cell-pic.webp?t=1589217567" type="image/png" medium="image" fileSize="558183">
        <media:title type="plain">Sickle cell illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears Shionogi’s Xocova as first COVID-19 prevention pill</title>
      <description>
        <![CDATA[The U.S. FDA approved Shionogi & Co. Ltd.’s Xocova (ensitrelvir) as the first oral post-exposure prophylactic option in the U.S. to prevent COVID-19, with the decision coming ahead of a PDUFA target date of June 16.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731531</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731531-fda-clears-shionogis-xocova-as-first-covid-19-prevention-pill</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Xocova-blister-pack.webp?t=1780425132" type="image/jpeg" medium="image" fileSize="147892">
        <media:title type="plain">Xocova blister pack</media:title>
        <media:description type="plain">Credit: Shionogi &amp;amp; Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Travere expands rare kidney portfolio in $1B+ Everest deal </title>
      <description>
        <![CDATA[Less than two months after winning FDA approval for a second indication for Filspari (sparsentan), Travere Therapeutics Inc. added to its rare kidney disease pipeline by exclusively licensing civorebrutinib from Everest Medicines Ltd. in a deal that could be worth more than $1.14 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731526</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731526-travere-expands-rare-kidney-portfolio-in-1b-everest-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Nephrology-Renal-Kidney.webp?t=1669825127" type="image/png" medium="image" fileSize="946164">
        <media:title type="plain">3D illustration of kidney cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>Cancer specter looming, Abtect effect in UC wallops Abivax</title>
      <description>
        <![CDATA[Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up in phase III top-line data from the Abtect maintenance trial with obefazimod. Paris-based Abivax SA’s oral, first-in-class miRNA-124 enhancer performed well in adults with moderately to severely active ulcerative colitis (UC), but shares of (NASDAQ:ABVX) closed June 2 at $72.50, down 44%, or $57.19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731525</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731525-cancer-specter-looming-abtect-effect-in-uc-wallops-abivax</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Stomach-pain.webp?t=1745258577" type="image/jpeg" medium="image" fileSize="208753">
        <media:title type="plain">Person holding stomach in pain </media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: A revolution in pancreatic cancer </title>
      <description>
        <![CDATA[At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the phase III RASolute 302 study of its pan-RAS inhibitor daraxonrasib in patients with previously treated, metastatic pancreatic ductal adenocarcinoma. The results were simultaneously published in <em>The New England Journal of Medicine</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731516</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731516-asco-2026-a-revolution-in-pancreatic-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas-3D-hologram.webp?t=1780342546" type="image/jpeg" medium="image" fileSize="208024">
        <media:title type="plain">Pancreas 3D hologram</media:title>
      </media:content>
    </item>
    <item>
      <title>Edgewise sells muscular dystrophy assets to Servier for $2.65B</title>
      <description>
        <![CDATA[Edgewise Therapeutics Inc. is pulling in $1.55 billion up front by selling its muscular dystrophy business, including its fast skeletal myosin inhibitor, sevasemten (EDG-5506), to Servier SA. The deal is potentially worth up to $2.65 billion when including a potential $1.1 billion in milestone payments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731512</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731512-edgewise-sells-muscular-dystrophy-assets-to-servier-for-265b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Purple-pie-chart.webp?t=1706041689" type="image/jpeg" medium="image" fileSize="65416">
        <media:title type="plain">Purple pie chart </media:title>
      </media:content>
    </item>
    <item>
      <title>Oculis shifts focus after phase III DME disappointment</title>
      <description>
        <![CDATA[The much-awaited phase III readout from Oculis Holding AG’s OCS-01 in diabetic macular edema (DME) fell short of expectations, delaying the possibility of a topical eye drop option for DME patients and prompting the company to shuffle its pipeline priorities, with a focus on late-stage programs targeting optic neuropathies and dry eye disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731510</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731510-oculis-shifts-focus-after-phase-iii-dme-disappointment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eyedrops.webp?t=1620150844" type="image/png" medium="image" fileSize="518130">
        <media:title type="plain">Woman using eyedrops</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS’ mezigdomide doubles PFS in multiple myeloma</title>
      <description>
        <![CDATA[Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma was successful. Nearly three months later, the magnitude of success for its Pomalyst (pomalidomide) successor is clear.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731454</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731454-bms-mezigdomide-doubles-pfs-in-multiple-myeloma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Multiple-myeloma---healthy-and-cancerous-bone-marrow.webp?t=1780089558" type="image/jpeg" medium="image" fileSize="209895">
        <media:title type="plain">Healthy (left) vs. cancerous bone marrow</media:title>
      </media:content>
    </item>
    <item>
      <title>Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections</title>
      <description>
        <![CDATA[GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731439</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731439-breakthrough-as-gsks-bepirovirsen-clears-19-of-chronic-hep-b-infections</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Liver-with-hepatitis-viruses.webp?t=1779996120" type="image/jpeg" medium="image" fileSize="162084">
        <media:title type="plain">Liver with hepatitis viruses, blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Kennedy offers emergency immunity for use of MCM in hantavirus</title>
      <description>
        <![CDATA[Acknowledging that the spread of the Andes virus and the resulting disease, hantavirus pulmonary syndrome, “constitutes a credible risk of a future public health emergency,” U.S. Health and Human Services Secretary Robert Kennedy is issuing a declaration to provide liability protection for manufacturers, distributors and providers using favipiravir as a medical countermeasure (MCM) against the virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731406</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731406-kennedy-offers-emergency-immunity-for-use-of-mcm-in-hantavirus</link>
    </item>
    <item>
      <title>AhR you ready for this? A new (or not-so-new) approach in UC </title>
      <description>
        <![CDATA[Upbeat phase II news lately from Spyre Therapeutics Inc. in inflammatory bowel disease (IBD) perked not only the company’s stock but also wider interest in the buzzing space, where developers big and small are trying to tackle such chronic bedevilments as Crohn’s disease and ulcerative colitis (UC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731404</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731404-ahr-you-ready-for-this-a-new-or-not-so-new-approach-in-uc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/3D-illustration-of-human-digestive-system.webp?t=1709246262" type="image/jpeg" medium="image" fileSize="171684">
        <media:title type="plain">3D illustration of human digestive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline </title>
      <description>
        <![CDATA[Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat <em>H. pylori</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731470</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731470-tennors-80m-hong-kong-ipo-to-fund-antibacterial-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotics-petri-dish.webp?t=1588349786" type="image/png" medium="image" fileSize="499611">
        <media:title type="plain">Petri dish and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>MEK inhibitor delivers 17.3-month OS for pancreatic cancer </title>
      <description>
        <![CDATA[Immuneering Corp. reported a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with its MEK inhibitor atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel in a phase IIa trial. Mizuho analyst Graig Suvannavejh called the results “astounding … easily beating current standard-of-care treatments.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/731386</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731386-mek-inhibitor-delivers-173-month-os-for-pancreatic-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/pancreatic-cancer-pancreas-3D.webp?t=1729610305" type="image/jpeg" medium="image" fileSize="283423">
        <media:title type="plain">Illustration of cancer in the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline </title>
      <description>
        <![CDATA[Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat <em>H. pylori</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731374</guid>
      <pubDate>Thu, 21 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731374-tennors-80m-hong-kong-ipo-to-fund-antibacterial-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotics-petri-dish.webp?t=1588349786" type="image/png" medium="image" fileSize="499611">
        <media:title type="plain">Petri dish and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731364</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731364-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Daewoong-Innovo-CEOs-5-13.webp?t=1778686979" type="image/jpeg" medium="image" fileSize="116766">
        <media:title type="plain">Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong</media:title>
        <media:description type="plain">Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731362</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731362-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Vincentage’s oral GLP-1 meets phase III obesity endpoints   </title>
      <description>
        <![CDATA[Vincentage Pharma Co. Ltd.’s once-daily oral small-molecule GLP-1 receptor agonist, VCT-220, met the primary endpoints in a pivotal phase III trial in overweight or obese patients in China. Based on the top-line data, the Chengdu, China-based company plans to submit an NDA for chronic weight management to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731330</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731330-vincentages-oral-glp-1-meets-phase-iii-obesity-endpoints</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>Relay’s zovegalisib hits in phase II vascular anomalies trial</title>
      <description>
        <![CDATA[Showing a significant efficacy signal in a phase II trial, Relay Therapeutics Inc.’s zovegalisib (RLY-2608) achieved a 60% volumetric response in patients with PIK3CA-driven vascular anomalies (VAs). The isoform-selective PI3Ka inhibitor is in late-stage clinical trials with various combinations for P13Ka-mutated, HR+/HER2- advanced breast cancer, with VAs representing a second indication for which Leerink Partners analyst Andrew Berens forecasts $2.8 billion in peak revenues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731325</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731325-relays-zovegalisib-hits-in-phase-ii-vascular-anomalies-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-vessels-veins-and-arteries.webp?t=1771963864" type="image/jpeg" medium="image" fileSize="111333">
        <media:title type="plain">Blood vessels, veins and arteries</media:title>
      </media:content>
    </item>
    <item>
      <title>New hypertension option as Astrazeneca’s Baxfendy wins FDA nod</title>
      <description>
        <![CDATA[Patients on antihypertensive medications who still struggle with high blood pressure now have a new treatment option, following the U.S. FDA’s approval of Astrazeneca plc’s baxdrostat. Branded Baxfendy, the drug is a first-in-class aldosterone synthase inhibitor, though it could be joined soon by potential competitor Mineralys Therapeutics Inc., which has a December 2026 PDUFA date for its aldosterone synthase inhibitor, lorundrostat.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731309</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731309-new-hypertension-option-as-astrazenecas-baxfendy-wins-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-pressure-cuff.webp?t=1709666702" type="image/png" medium="image" fileSize="439332">
        <media:title type="plain">Blood pressure cuff </media:title>
      </media:content>
    </item>
    <item>
      <title>Validity of Actelion patent hinges on temperature </title>
      <description>
        <![CDATA[Temperature matters when determining pH levels. Whether that level should be measured at a standard room temperature or refrigerated matters even more, at least in Actelion Ltd.’s infringement litigation against Mylan Inc. According to Johnson & Johnson’s Actelion, the pH level in epoprostenol, the key ingredient in its hypertension drug Veletri, should be measured at a refrigerated temperature when it comes to Mylan’s generic formulation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731211</guid>
      <pubDate>Fri, 15 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731211-validity-of-actelion-patent-hinges-on-temperature</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/pH-testing.webp?t=1778865955" type="image/jpeg" medium="image" fileSize="74585">
        <media:title type="plain">Test tube and pH chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731194</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731194-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone’s BCL2 drug Beqalzi wins FDA nod in mantle cell lymphoma </title>
      <description>
        <![CDATA[A few months after winning its first regulatory clearance in China, Beone Medicines Inc.’s next-generation BCL2 inhibitor, sonrotoclax, gained the U.S. FDA’s accelerated approval for use in patients with relapsed or refractory mantle cell lymphoma (MCL) following treatment with a BTK inhibitor. The therapy, branded Beqalzi, marks the first BCL2-targeting drug for MCL in the U.S., but the company has pointed to a bigger opportunity in the potential combination with blockbuster BTK drug Brukinsa (zanubrutinib).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731062</guid>
      <pubDate>Wed, 13 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731062-beones-bcl2-drug-beqalzi-wins-fda-nod-in-mantle-cell-lymphoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Mantle-cell-lymphoma.webp?t=1745257483" type="image/jpeg" medium="image" fileSize="485333">
        <media:title type="plain">Mantle cell lymphoma </media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731063</guid>
      <pubDate>Wed, 13 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731063-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Daewoong-Innovo-CEOs-5-13.webp?t=1778686979" type="image/jpeg" medium="image" fileSize="116766">
        <media:title type="plain">Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong</media:title>
        <media:description type="plain">Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong.</media:description>
      </media:content>
    </item>
    <item>
      <title>Metis Techbio, Impact Tx cleared for Hong Kong IPOs</title>
      <description>
        <![CDATA[Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the largest biotech raise on the Hong Kong Stock Exchange this year to date. Hangzhou, China-based Metis is an AI-based nanoparticle drug formulation and delivery-focused company. Synthetic lethality-based cancer drugmaker Impact Therapeutics Inc., of Shanghai, plans to debut on the same day with a US$117 million IPO.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731048</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731048-metis-techbio-impact-tx-cleared-for-hong-kong-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Coming through on Veppanu with back-loaded Rigel deal</title>
      <description>
        <![CDATA[Rigel Pharmaceuticals Inc. CEO Raul Rodriguez said breast cancer therapy Veppanu (vepdegestrant) could become his firm’s “largest product with the current label,” and other opportunities with the drug are lined up behind, albeit “still a bit early.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/731045</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731045-coming-through-on-veppanu-with-back-loaded-rigel-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign-inside-gold-cog.webp?t=1637008509" type="image/png" medium="image" fileSize="305471">
        <media:title type="plain">Gold dollar sign inside gold cog</media:title>
      </media:content>
    </item>
    <item>
      <title>Traws Pharma to advance hantavirus candidates</title>
      <description>
        <![CDATA[Traws Pharma Inc. has announced plans to advance potential clinical candidates for the treatment of hantavirus infection. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730994</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730994-traws-pharma-to-advance-hantavirus-candidates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Futuristic-medicine-concept.webp?t=1778512452" type="image/jpeg" medium="image" fileSize="550890">
        <media:title type="plain">Futuristic medicine concept with glowing bottle pills, syringe, vial</media:title>
      </media:content>
    </item>
    <item>
      <title>Odyssey’s IPO, placement brings $304M to lead drugs in IBD, lupus</title>
      <description>
        <![CDATA[Raising $279 million in an IPO and another $25 million in a concurrent private placement, Odyssey Therapeutics Inc. is advancing its lead phase II asset, OD-001, in ulcerative colitis, with plans to bring its SLC15A4 program into the clinic for lupus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730980</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730980-odysseys-ipo-placement-brings-304m-to-lead-drugs-in-ibd-lupus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-coins.webp?t=1588705630" type="image/png" medium="image" fileSize="384858">
        <media:title type="plain">IPO, coins, financial chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst</title>
      <description>
        <![CDATA[Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition gives Angelini ownership of three marketed drugs for treating epilepsy and neuromuscular diseases that had combined sales of $589 million in 2025, a 19.8% increase over 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730965</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730965-italys-angelini-pays-41b-cash-for-rare-disease-specialist-catalyst</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neuro-illustration.webp?t=1628534498" type="image/png" medium="image" fileSize="616001">
        <media:title type="plain">Neurology illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Bayer buying Perfuse for $300M up front in potential $2.45B deal </title>
      <description>
        <![CDATA[In its first substantial M&A transaction since 2021, Bayer AG is buying Perfuse Therapeutics Inc., a firm that has operated quietly, though it reported positive midstage data last year for PER-001, an endothelin antagonist, in glaucoma and diabetic retinopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730862</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730862-bayer-buying-perfuse-for-300m-up-front-in-potential-245b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-financial-charts.webp?t=1685051887" type="image/jpeg" medium="image" fileSize="207505">
        <media:title type="plain">Eye and financial charts</media:title>
      </media:content>
    </item>
    <item>
      <title>TMLZ-G46 shows strong antitumor effects in glioma</title>
      <description>
        <![CDATA[Gliomas are malignant tumors in the brain characterized by aggressive growth, poor prognosis and high mortality, and for which effective therapies are still lacking. Zinc finger protein 207 (ZNF207) is highly expressed in gliomas and represents a promising therapeutic target; researchers from the China Pharmaceutical University have developed and presented data for the ZNF207 inhibitor TMLZ-G46.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730884</guid>
      <pubDate>Tue, 05 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730884-tmlz-g46-shows-strong-antitumor-effects-in-glioma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/3d-medically-accurate-human-brain-tumor.webp?t=1731428528" type="image/jpeg" medium="image" fileSize="229906">
        <media:title type="plain">3D illustration of brain cancer</media:title>
      </media:content>
    </item>
  </channel>
</rss>
